FY2025 Earnings Estimate for CLDX Issued By HC Wainwright

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Celldex Therapeutics in a report released on Wednesday, November 20th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($2.99) for the year, up from their prior estimate of ($3.02). HC Wainwright currently has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.45) per share.

A number of other research analysts have also recently commented on the stock. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective for the company. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Trading Up 3.1 %

NASDAQ CLDX opened at $27.02 on Friday. Celldex Therapeutics has a 1 year low of $22.93 and a 1 year high of $53.18. The firm’s 50 day simple moving average is $30.56 and its 200 day simple moving average is $35.02. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -10.24 and a beta of 1.60.

Insider Transactions at Celldex Therapeutics

In related news, CEO Anthony S. Marucci purchased 11,500 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average cost of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV grew its stake in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Celldex Therapeutics during the second quarter worth about $76,000. CANADA LIFE ASSURANCE Co increased its stake in shares of Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares in the last quarter. Finally, Quest Partners LLC raised its position in shares of Celldex Therapeutics by 1,364.9% in the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 6,879 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.